Saturday 17 October 2026
Export TSHA’s income statement to Excel — free account
Taysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024. In the quarter to June 2026, revenue grew 206.8%, EPS fell 44.4%, free cash flow fell 100.3% and total debt rose 20.0%, each against the same quarter a year earlier.
3.62
0.11
−2.95%
Follow TSHA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
— | — | 149.08 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (65.80) | — | |
P/B ratio |
— | — | 7.12 | — | |
Price to Tangible BV |
— | — | 7.12 | — | |
EV/Sales |
— | — | 126.18 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (15.99) | — | |
EV/FCF |
— | — | (15.14) | — | |
Quick Ratio |
17.53 | 13.78 | 12.06 | 10.40 | |
Current Ratio |
17.76 | 14.04 | 12.23 | 10.48 | |
Net Debt/EBITDA |
8.63 | 5.28 | 9.65 | 7.32 | |
Debt/Assets |
10.47% | 16.30% | 14.59% | 16.06% | |
Debt/Equity |
0.13 | 0.23 | 0.20 | 0.23 | |
Asset Turnover |
0.00 | 0.00 | 0.05 | 0.00 | |
Operating CF/Net income |
0.87 | 0.96 | 0.96 | 0.74 | |
Capex/Depreciation |
0.00 | (10.25) | (0.84) | (0.38) | |
Interest Coverage |
(7,891.50) | (4,831.78) | (2,358.33) | (2,268.27) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 454.91% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 161.04% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 64.34% | 0.00% | |
Graham Net Nets |
— | — | 0.13 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (6.18%) | — | |
Free Cash Flow Yield |
— | — | (5.59%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.02 | 0.00 | |
Operating CF per Share |
(0.11) | (0.11) | (0.08) | (0.07) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.12) | (0.08) | (0.07) | |
Cash per Share |
1.23 | 0.76 | 1.00 | 0.84 | |
Shareholders Equity per Share |
1.05 | 0.58 | 0.77 | 0.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.05 | 0.58 | 0.77 | 0.62 | |
Free Cash Flow |
(40.42) | (43.90) | (26.97) | (24.27) | |
Working Capital |
435.46 | 262.15 | 298.10 | 271.32 | |
Capital Expenditures |
0.00 | (3.02) | (0.25) | (0.11) | |
Net Current Asset Value |
378.27 | 193.84 | 228.27 | 202.39 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
8.44 | 4.45 | 4.93 | 5.19 | |
Average Assets |
401.88 | 219.36 | 251.84 | 248.39 | |
Average Common Equity |
318.00 | 133.50 | 159.23 | 153.89 |
Columns are period end dates